BACKGROUND: The association between bleeding severity and cause of mortality in the non-acute setting is unclear. We sought to investigate the association between bleeding and mortality subtype, and assess whether this association differs in patients on dual antiplatelet therapy (DAPT) versus aspirin alone. METHODS: Using multivariable Cox proportional hazards survival regression, we examined the association between moderate or severe bleeding and all-cause, cardiovascular, and cancer mortality in 15,603 patients with cardiovascular disease or multiple risk factors enrolled in the CHARISMA trial. RESULTS:Patients with moderate or severe bleeding had a higher incidence of all-cause, cardiovascular, and cancer mortality (P < .001 for each). After multivariable adjustment, moderate/severe bleeding remained independently associated with not only all-cause mortality (adjusted hazard ratio [HR] 1.66; 95% confidence interval [CI] 1.24-2.21) and cardiovascular mortality (HR 2.05, 95% CI 1.38-3.04) but also cancer mortality (HR 4.76, 95% CI 2.60-8.69). However, there was a significant interaction between bleeding and potency of antiplatelet therapy for all-cause (P = .002), cardiovascular (P = .02), and cancer mortality (P = .03); in subjects on aspirin alone, moderate/severe bleeding was associated with all-cause (HR 5.27, 95% CI 3.56-7.80), cardiovascular (HR 4.33, 95% CI 2.55-7.37), and cancer mortality (HR 9.01, 95% CI 4.41-18.43), but not in subjects on DAPT (all-cause: HR 1.48, 95% CI 0.93-2.34; cardiovascular: HR 1.04, 95% CI 0.58-1.86; and cancer mortality: HR 1.79, 95% CI 0.56-5.74). CONCLUSIONS: In stable patients, moderate or severe bleeding is associated with a significantly increased risk of all-cause, cardiovascular, and cancer mortality. However, this risk appeared different in subjects on single antiplatelet therapy versus DAPT.
RCT Entities:
BACKGROUND: The association between bleeding severity and cause of mortality in the non-acute setting is unclear. We sought to investigate the association between bleeding and mortality subtype, and assess whether this association differs in patients on dual antiplatelet therapy (DAPT) versus aspirin alone. METHODS: Using multivariable Cox proportional hazards survival regression, we examined the association between moderate or severe bleeding and all-cause, cardiovascular, and cancer mortality in 15,603 patients with cardiovascular disease or multiple risk factors enrolled in the CHARISMA trial. RESULTS:Patients with moderate or severe bleeding had a higher incidence of all-cause, cardiovascular, and cancer mortality (P < .001 for each). After multivariable adjustment, moderate/severe bleeding remained independently associated with not only all-cause mortality (adjusted hazard ratio [HR] 1.66; 95% confidence interval [CI] 1.24-2.21) and cardiovascular mortality (HR 2.05, 95% CI 1.38-3.04) but also cancer mortality (HR 4.76, 95% CI 2.60-8.69). However, there was a significant interaction between bleeding and potency of antiplatelet therapy for all-cause (P = .002), cardiovascular (P = .02), and cancer mortality (P = .03); in subjects on aspirin alone, moderate/severe bleeding was associated with all-cause (HR 5.27, 95% CI 3.56-7.80), cardiovascular (HR 4.33, 95% CI 2.55-7.37), and cancer mortality (HR 9.01, 95% CI 4.41-18.43), but not in subjects on DAPT (all-cause: HR 1.48, 95% CI 0.93-2.34; cardiovascular: HR 1.04, 95% CI 0.58-1.86; and cancer mortality: HR 1.79, 95% CI 0.56-5.74). CONCLUSIONS: In stable patients, moderate or severe bleeding is associated with a significantly increased risk of all-cause, cardiovascular, and cancer mortality. However, this risk appeared different in subjects on single antiplatelet therapy versus DAPT.
Authors: Nina A Hilkens; Ale Algra; Hans-Christoph Diener; Johannes B Reitsma; Philip M Bath; Laszlo Csiba; Werner Hacke; L Jaap Kappelle; Peter J Koudstaal; Didier Leys; Jean-Louis Mas; Ralph L Sacco; Pierre Amarenco; Leila Sissani; Jacoba P Greving Journal: Neurology Date: 2017-08-02 Impact factor: 9.910
Authors: Jannik S Pedersen; Martin S Laursen; Thiusius Rajeeth Savarimuthu; Rasmus Søgaard Hansen; Anne Bryde Alnor; Kristian Voss Bjerre; Ina Mathilde Kjær; Charlotte Gils; Anne-Sofie Faarvang Thorsen; Eline Sandvig Andersen; Cathrine Brødsgaard Nielsen; Lou-Ann Christensen Andersen; Søren Andreas Just; Pernille Just Vinholt Journal: Res Pract Thromb Haemost Date: 2021-05-05
Authors: Pedro A Villablanca; Daniele Massera; Verghese Mathew; Sripal Bangalore; Panagiota Christia; Irving Perez; Ningxin Wan; Stefanie Schulz-Schüpke; David F Briceno; Anna E Bortnick; Mario J Garcia; Richard Lucariello; Mark Menegus; Robert Pyo; Jose Wiley; Harish Ramakrishna Journal: Medicine (Baltimore) Date: 2016-12 Impact factor: 1.889
Authors: Aydin Huseynov; Michael Behnes; Uzair Ansari; Stefan Baumann; Dirk Lossnitzer; Ibrahim El-Battrawy; Christian Fastner; Martin Borggrefe; Ibrahim Akin Journal: J Geriatr Cardiol Date: 2019-11 Impact factor: 3.327
Authors: Nina A Hilkens; Ale Algra; L Jaap Kappelle; Philip M Bath; László Csiba; Peter M Rothwell; Jacoba P Greving Journal: Neurology Date: 2018-01-26 Impact factor: 9.910
Authors: Maxwell Taggart; Wendy W Chapman; Benjamin A Steinberg; Shane Ruckel; Arianna Pregenzer-Wenzler; Yishuai Du; Jeffrey Ferraro; Brian T Bucher; Donald M Lloyd-Jones; Matthew T Rondina; Rashmee U Shah Journal: JAMA Netw Open Date: 2018-10-05